HATFIELD, HERTFORDSHIRE, UNITED KINGDOM (UK), and MAIDENHEAD, UK, 7 JULY 2025 – Eisai Europe Ltd. and Biogen Idec Ltd. announced today that the Scottish Medicines Consortium (SMC) has not recommended ...

Biogen shares slipped on Monday after the company said it expects to take a $46 million charge in the second quarter related ...

The company estimated that more than 1000 women in Scotland at very high risk of fracture would be eligible for treatment.

The FDA’s regular communications based on reports from its drug safety report database don’t always rattle investors’ cages.

INmune Bio said that a subset of Alzheimer's disease patients in the study showed clinical benefit from the therapy.

In the case of the amyloid drugs, Eisai Biogen's Leqembi (lecanemab) and Eli Lilly's Kisunla (donanemab) – there are also ...

Digging into a prespecified analysis for the mid-stage study, INmune Bio identified some clinical and biological benefits of ...

RBC Capital Markets analysts believe Eli Lilly’s upcoming TRAILBLAZER-3 trial data on Kisunla could unlock a vast, largely untapped segment of the Alzheimer’s treatment market and pave the way for ...

(Reuters) -INmune Bio said on Monday its experimental Alzheimer's drug failed to improve cognitive functions in patients with ...

Treatments for Alzheimer's approved so far, including Eisai and Biogen's Leqembi, and Eli Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They also ...

Diagnosing Alzheimer’s is difficult, and precise biomarkers are needed to assist physicians in making accurate assessments, ...

Biogen’s first quarter results outpaced Wall Street’s expectations, prompting a positive market reaction. Management ...